Detalles de la búsqueda
1.
Blood pressure monitoring in elderly migraineurs starting an anti-CGRP monoclonal antibody: a real-world prospective study.
Neurol Sci
; 2024 May 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-38795273
2.
Real-world effectiveness of Anti-CGRP monoclonal antibodies compared to OnabotulinumtoxinA (RAMO) in chronic migraine: a retrospective, observational, multicenter, cohort study.
J Headache Pain
; 25(1): 14, 2024 Feb 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-38308209
3.
Maintenance of response and predictive factors of 1-year GalcanezumAb treatment in real-life migraine patients in Italy: The multicenter prospective cohort GARLIT study.
Eur J Neurol
; 30(1): 224-234, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36097739
4.
Calcitonin Gene-Related Peptide Systemic Effects: Embracing the Complexity of Its Biological Roles-A Narrative Review.
Int J Mol Sci
; 24(18)2023 Sep 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-37762283
5.
Rapid response to galcanezumab and predictive factors in chronic migraine patients: A 3-month observational, longitudinal, cohort, multicenter, Italian real-life study.
Eur J Neurol
; 29(4): 1198-1208, 2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-34826192
6.
Improving distress perception and mutuality in migraine caregivers after 6 months of galcanezumab treatment.
Headache
; 62(9): 1143-1147, 2022 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-36205100
7.
Gepants - a long way to cure: a narrative review.
Neurol Sci
; 43(9): 5697-5708, 2022 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-35650458
8.
Task-switching abilities in episodic and chronic migraine.
Neurol Sci
; 43(6): 3803-3810, 2022 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-35064344
9.
Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study).
J Headache Pain
; 23(1): 46, 2022 Apr 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-35397503
10.
Predictors of response to anti-CGRP monoclonal antibodies: a 24-week, multicenter, prospective study on 864 migraine patients.
J Headache Pain
; 23(1): 138, 2022 Nov 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36316648
11.
Comparing the relative and absolute effect of erenumab: is a 50% response enough? Results from the ESTEEMen study.
J Headache Pain
; 23(1): 38, 2022 Mar 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-35305579
12.
Erenumab does not alter cerebral hemodynamics and endothelial function in migraine without aura.
Cephalalgia
; 41(1): 90-98, 2021 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32867533
13.
Erenumab in the prevention of high-frequency episodic and chronic migraine: Erenumab in Real Life in Italy (EARLY), the first Italian multicenter, prospective real-life study.
Headache
; 61(2): 363-372, 2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33337544
14.
Long-term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high-frequency episodic and chronic migraine in a real world: Results of the EARLY 2 study.
Headache
; 61(9): 1351-1363, 2021 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-34309862
15.
Clinical features, disease progression, and use of healthcare resources in a large sample of 866 patients from 24 headache centers: A real-life perspective from the Italian chROnic migraiNe (IRON) project.
Headache
; 61(6): 936-950, 2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-34125953
16.
Discontinuing monoclonal antibodies targeting CGRP pathway after one-year treatment: an observational longitudinal cohort study.
J Headache Pain
; 22(1): 154, 2021 Dec 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-34922444
17.
Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study).
J Headache Pain
; 22(1): 35, 2021 May 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-33941080
18.
Locking down the CGRP pathway during the COVID-19 pandemic lockdown: the PandeMig study.
Neurol Sci
; 41(12): 3385-3389, 2020 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-33001407
19.
Right-to-Left Shunt and the Clinical Features of Migraine with Aura: Earlier but Not More.
Cerebrovasc Dis
; 47(5-6): 268-274, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-31357200
20.
Onabotulinumtoxin-A in Chronic Migraine: Should Timing and Definition of Non-Responder Status Be Revised? Suggestions From a Real-Life Italian Multicenter Experience.
Headache
; 59(8): 1300-1309, 2019 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-31454075